4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Aprea Therapeutics, Inc. (APRE) operates in the Biotechnology industry and is headquartered in Doylestown, United States with about 8 employees. Its market capitalization is roughly $8 million. In the fiscal year ended 2025-12-31, APRE reported $0M in revenue and ($13M) in net income.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
Interactive charts & full statements → Open the APRE valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($13M) | ($14M) | ($16M) | ($37M) | — |
| Net Income | ($13M) | ($13M) | ($14M) | ($113M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($3M) | ($3M) | ($3M) | ($3M) | ($4M) | — |
| Net Income | ($3M) | ($2M) | ($3M) | ($3M) | ($4M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $16M | $24M | $23M | $30M | — |
| Total Liabilities | $4M | $5M | $6M | $4M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive APRE viewer.
About TickerBase · Data methodology & sources